Evidence map›Paper›PMID 36939946›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2023

Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ).

Agnese Onofri, Luigi Francesco Iannone, Antonio Granato, Gabriele Garascia, Luca Bartole, Paolo Manganotti, Catello Vollono, Marina Romozzi, Costanza Sottani, Paolo Calabresi and 23 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 13 institutions in 2 countries.

Agnese OnofriDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy.
Luigi Francesco IannoneSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Antonio GranatoHeadache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.
Gabriele GarasciaHeadache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.
Luca BartoleHeadache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.
Paolo ManganottiHeadache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.
Catello VollonoFondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Marina RomozziFondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Costanza SottaniFondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Paolo CalabresiFondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Cristina TassorelliDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Grazia SancesHeadache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.
Marta AllenaHeadache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.
Roberto De IccoDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Francesco De CesarisSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Andrea BurgalassiSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Alberto ChiarugiSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Carlo BaraldiDepartment of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.
Simona GuerzoniDepartment of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.
Maria Pia PrudenzanoHeadache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.
Adriana FallacaraHeadache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.
Maria AlbaneseRegional Referral Headache Center, Neurology Unit, University Hospital Tor Vergata, 00133, Rome, Italy.
Innocenzo RaineroHeadache Center, Department of Neuroscience "Rita Levi Montalcini", University of Torino, Turin, Italy.
Gianluca CoppolaDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina, Italy.
Alfonsina CasalenaNeurology Unit, "G. Mazzini" Hospital, Teramo, Italy.
Edoardo MampresoHeadache Centre, Neurology - Euganea, Health Unit, Padua, Padua, Italy.
Francesca PistoiaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy.
Paola SarchielliSection of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Marisa MorsonItalian Society for the Study of Headache (SISC), Rome, Italy.
Simona SaccoDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy.
Pierangelo GeppettiSection of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Raffaele OrnelloDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy. raffaele.ornello@univaq.it.ORCID http://orcid.org/0000-0001-9501-4031
Italian Headache Registry (RICe) Study Group
University of Florence · ITUniversità Cattolica del Sacro Cuore · ITUniversity of L'Aquila · ITUniversity of Trieste · ITAzienda Ospedaliero-Universitaria di Modena · ITFondazione Istituto Neurologico Nazionale Casimiro Mondino · ITUniversity of Bari Aldo Moro · ITUniversity of Pavia · ITNini Hospital · LBSapienza University of Rome · ITUniversity of Perugia · ITUniversity of Rome Tor Vergata · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Cluster Headache Impact Questionnaire (CHIQ) is a specific and easy-to-use questionnaire to assess the current impact of cluster headache (CH). The aim of this study was to validate the Italian version of the CHIQ.

methodsWe included patients diagnosed with episodic CH (eCH) or chronic CH (cCH) according to the ICHD-3 criteria and included in the "Italian Headache Registry" (RICe). The questionnaire was administered to patients through an electronic form in two sessions: at first visit for validation, and after 7 days for test-retest reliability. For internal consistency, Cronbach's alpha was calculated. Convergent validity of the CHIQ with CH features and the results of questionnaires assessing anxiety, depression, stress, and quality of life was evaluated using Spearman's correlation coefficient.

resultsWe included 181 patients subdivided in 96 patients with active eCH, 14 with cCH, and 71 with eCH in remission. The 110 patients with either active eCH or cCH were included in the validation cohort; only 24 patients with CH were characterized by a stable attack frequency after 7 days, and were included in the test-retest cohort. Internal consistency of the CHIQ was good with a Cronbach alpha value of 0.891. The CHIQ score showed a significant positive correlation with anxiety, depression, and stress scores, while showing a significant negative correlation with quality-of-life scale scores.

conclusionOur data show the validity of the Italian version of the CHIQ, which represents a suitable tool for evaluating the social and psychological impact of CH in clinical practice and research.

Indexed as

Cluster HeadacheHumansItalyPsychometricsQuality of LifeReproducibility of ResultsSurveys and QuestionnairesCluster headacheCluster Headache Impact QuestionnaireDisabilityQuality of lifeQuestionnaire

Identifiers

PMID36939946
PMCPMC10345064
OpenAlexW4327895836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.